A viral intermittent fasting study: what to know

The news is everywhere today: Intermittent fasting can apparently be lethal, scientific research says. Except it doesn't.

March 19, 2024 Check out STAT+

Sponsored By

Coming March 28, STAT is launching a new, subscriber-only weekly newsletter: Adam's Biotech Scorecard. Sign up now to receive Adam Feuerstein's no-holds-barred perspective on the rapidly shifting world of biotech straight to your inbox.

Thumy Phan for STAT STAT+ | The methadone clinic monopoly: Opioid treatment chains backed by private equity are fighting calls for reform A first-of-its-kind analysis by STAT finds that a handful of private equity firms own nearly a third of U.S. methadone clinics. By Lev Facher A study says intermittent fasting is making people drop dead. Oh, come on A new study garnering attention is a type of nutritional research that is notoriously weak, and right now it's only available as a press release. By Matthew Herper STAT+ | UnitedHealth appears to be upping loan offers to providers, after Change cyberattack Nearly a month after a crippling cyberattack on Change Healthcare, parent company UnitedHealth significantly increases loans to cash-strapped providers. By Brittany Trang and Tara Bannow Adobe Opinion: The evidence is clear: A liquid-only diet before a colonoscopy is unnecessary Patients who eat a "low-residue diet" before a colonoscopy get just as good results — and are less likely to cancel their procedures. By Benjamin Lebwohl STAT+ | Q&A: Mark Parrino says it's time to 'completely re-examine' methadone treatment for opioid addiction Mark Parrino, chief voice for opioid treatment programs, explains the rationale for the clinics' exclusive right to dispense methadone. By Lev Facher STAT+ | In small study, baby aspirin cuts fat buildup in liver disease patients Although more research is needed, the study suggests that baby aspirin could help some patients with metabolic liver disease, or MASLD.  By Isabella Cueto Alastair Grant/AP STAT+ | As targeted radiation field heats up, AstraZeneca to acquire Fusion Pharmaceuticals in $2 billion deal The $2 billion deal is the latest sign that the radiopharmaceuticals field of cancer treatments is booming. By Andrew Joseph

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser